Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Rating of “Moderate Buy” by Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $9.27.

A number of research firms have commented on HCAT. Royal Bank of Canada reduced their target price on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. Stephens reduced their target price on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a report on Wednesday, January 8th. Canaccord Genuity Group reduced their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 21st. Finally, Wells Fargo & Company reduced their target price on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st.

Insider Transactions at Health Catalyst

In related news, Director Duncan Gallagher sold 4,500 shares of Health Catalyst stock in a transaction on Monday, December 30th. The stock was sold at an average price of $6.93, for a total transaction of $31,185.00. Following the transaction, the director now directly owns 69,938 shares in the company, valued at approximately $484,670.34. The trade was a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Linda Llewelyn sold 6,441 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the transaction, the insider now owns 85,819 shares in the company, valued at $465,997.17. The trade was a 6.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,243 shares of company stock worth $273,620 in the last ninety days. Insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Several large investors have recently made changes to their positions in HCAT. Quantbot Technologies LP bought a new stake in shares of Health Catalyst in the fourth quarter worth about $29,000. Quest Partners LLC purchased a new stake in shares of Health Catalyst in the third quarter worth approximately $34,000. Group One Trading LLC raised its holdings in shares of Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after buying an additional 2,260 shares during the period. Aquatic Capital Management LLC bought a new position in Health Catalyst in the fourth quarter worth approximately $63,000. Finally, Quadrature Capital Ltd bought a new position in Health Catalyst in the third quarter worth approximately $84,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Stock Down 3.2 %

HCAT stock opened at $4.29 on Wednesday. Health Catalyst has a twelve month low of $3.76 and a twelve month high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market cap of $301.21 million, a PE ratio of -3.18 and a beta of 1.41. The business has a 50 day moving average of $5.73 and a 200 day moving average of $7.16.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.